Open AccessStudy Sets Response Benchmarks for FLT3‐Inhibitor Sequencing in FLT3 ‐Mutated AML
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13648
Subject(s) - medicine , myeloid leukemia , fms like tyrosine kinase 3 , leukemia , cancer research , myeloid , oncology , mutation , immunology , gene , genetics , biology
A new study of sequential exposure to FLT3 inhibitors demonstrates the benefits of these therapies across multiple lines and treatment settings for patients with FLT3 ‐mutated acute myeloid leukemia.